Desensitization to lenalidomide;Desensibilización a lenalidomida

Farmacia Hospitalaria

Volumn 36, Issue 6, 2012, Pages 542-544

  Canamares Orbis I ^a   Garcia Munoz C ^a   Cortijo Cascajares, S ^a   Mendez Esteban M E ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE;

DESENSITIZATION; HUMAN; LETTER;

AGED; ANGIOGENESIS INHIBITORS; DESENSITIZATION, IMMUNOLOGIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84877781206     PISSN: 11306343     EISSN: 21718695     Source Type: Journal    
DOI: 10.7399/FH.2012.36.6.46     Document Type: Letter

References (6)

1. Scott LJ, Lyseng-Williamson KA. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs. 2011;71:625-49.
2. Alegre A, Oriol-Rocafiguera A, Duncan C, Garcia-Larana J, Mateos M V, Sureda A, et al. Efficacy, safety, and quality-of-life of lenalido-mide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. Leuk Lymphoma 2012 Feb 1 (Epub ahead of print).
3. ®. Laboratorios Celgene. Enero 2007. Disponible en: http://www.ema.europa.eu/docs/es-ES/document-li- brary/EPAR-Product-Information/human/000717/WC500056018.pdf
4. Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A, Campi P, Sanz ML, Castells M, Demoly P, Pichler WJ, for the European Network of Drug Allergy and the EAACI interest group on drug hypersensitivity. General considerations on rapid desensitiza-tion for drug hypersensitivity-a consensus statement. Allergy 2010;65:1357-66.
5. Castells M. Rapid desensitization for hypersensitivity reactions to medications. Immunology and allergy clinics of North America. 2009;29:585-606.
6. Phillips J, Kujawa J, Davis-Lorton M, Hindenburg A. Successful desensitization in a patient with lenalidomide hypersensitivity. Am J Hematol. 2007;82:1030.